NRXP NRX Pharmaceuticals Inc

Price (delayed)

$4.05

Market cap

$146.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$140.95M

?
Relative Growth: Rel. Growth: 23
Relative Strength: Rel. Strength: 92
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 13

Big Rock Partners is a blank check company formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination ...

Highlights
The revenue has soared by 87% since the previous quarter
The gross profit has surged by 61% since the previous quarter
NRX Pharmaceuticals's debt has plunged by 89% YoY but it has increased by 48% from the previous quarter
NRX Pharmaceuticals's quick ratio has soared by 59% YoY but it has decreased by 3.6% from the previous quarter
NRX Pharmaceuticals's gross margin has decreased by 14% from the previous quarter

Key stats

What are the main financial stats of NRXP

NRXP stock price

How has the NRX Pharmaceuticals stock price performed over time
Intraday
0%
1 week
-8.78%
1 month
35%
1 year
37.29%
YTD
49.45%
QTD
90.14%

Financial performance

How have NRX Pharmaceuticals's revenue and profit performed over time
Revenue
$2.29M
Gross profit
$1.16M
Operating income
-$17.12M
Net income
-$24.54M
Gross margin
50.5%
Net margin
-1,070.3%
The revenue has soared by 87% since the previous quarter
The gross profit has surged by 61% since the previous quarter
NRX Pharmaceuticals's net margin has soared by 54% from the previous quarter
NRX Pharmaceuticals's operating margin has increased by 44% QoQ

Price vs fundamentals

How does NRXP's price correlate with its fundamentals

Growth

What is NRX Pharmaceuticals's growth rate over time

Valuation

What is NRX Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
57.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
61.47
NRXP's EPS is up by 46% year-on-year and by 19% since the previous quarter
The company's equity rose by 45% YoY and by 13% QoQ
The revenue has soared by 87% since the previous quarter

Efficiency

How efficient is NRX Pharmaceuticals business performance
NRXP's return on sales has surged by 55% since the previous quarter
NRX Pharmaceuticals's ROA has soared by 52% YoY and by 23% from the previous quarter

Dividends

What is NRXP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRXP.

Financial health

How did NRX Pharmaceuticals financials performed over time
The total assets is 54% less than the total liabilities
NRX Pharmaceuticals's quick ratio has soared by 59% YoY but it has decreased by 3.6% from the previous quarter
The total assets has soared by 57% YoY but it has contracted by 8% from the previous quarter
NRX Pharmaceuticals's debt is 107% more than its equity
NRX Pharmaceuticals's debt has plunged by 89% YoY but it has increased by 48% from the previous quarter
The debt to equity has soared by 79% YoY but it has plunged by 75% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.